Pages that link to "Q125021748"

The following pages link to Arnold Louie (Q125021748):

Displaying 40 items.

• Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2 (Q26771848) (← links)
• Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1 (Q26771850) (← links)
• Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial (Q28277029) (← links)
• Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system (Q28477067) (← links)
• Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis (Q28540482) (← links)
• Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa (Q30775587) (← links)
• Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy (Q33427278) (← links)
• Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague (Q33798021) (← links)
• Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance (Q33876543) (← links)
• The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression (Q33876615) (← links)
• Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity (Q34228214) (← links)
• Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis (Q34228256) (← links)
• Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae (Q34301541) (← links)
• Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model (Q34736543) (← links)
• Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States (Q34922218) (← links)
• Optimization of Aminoglycoside Therapy (Q35005127) (← links)
• Comparative Efficacies of Candidate Antibiotics against Yersinia pestis in an In Vitro Pharmacodynamic Model (Q35005186) (← links)
• Dose Range Evaluation of Mycograb C28Y Variant, a Human Recombinant Antibody Fragment to Heat Shock Protein 90, in Combination with Amphotericin B-Desoxycholate for Treatment of Murine Systemic Candidiasis (Q35065740) (← links)
• In Vivo Pharmacodynamics of Torezolid Phosphate (TR-701), a New Oxazolidinone Antibiotic, against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Strains in a Mouse Thigh Infection Model (Q35065908) (← links)
• Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis (Q35127833) (← links)
• Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect (Q35127913) (← links)
• Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy (Q35140423) (← links)
• Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model (Q35364245) (← links)
• Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia (Q35647785) (← links)
• Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia (Q35661926) (← links)
• Differential Effects of Linezolid and Ciprofloxacin on Toxin Production by Bacillus anthracis in an In Vitro Pharmacodynamic System (Q35666418) (← links)
• Resistance Emergence Mechanism and Mechanism of Resistance Suppression by Tobramycin for Cefepime for Pseudomonas aeruginosa (Q35666434) (← links)
• Impact of Spores on the Comparative Efficacies of Five Antibiotics for Treatment of Bacillus anthracis in an In Vitro Hollow Fiber Pharmacodynamic Model (Q35806278) (← links)
• Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy (Q35912654) (← links)
• Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice (Q36644836) (← links)
• Back to the future: using aminoglycosides again and how to dose them optimally (Q36916092) (← links)
• Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant (Q37204214) (← links)
• Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets (Q37274632) (← links)
• Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children (Q37335844) (← links)
• Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a NovelIn VitroPharmacodynamic System (Q39430698) (← links)
• Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases (Q40328633) (← links)
• Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model (Q40601946) (← links)
• In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae (Q41899401) (← links)
• The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model (Q42529609) (← links)
• Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis? (Q43251072) (← links)